JP2022542447A5 - - Google Patents

Info

Publication number
JP2022542447A5
JP2022542447A5 JP2022506467A JP2022506467A JP2022542447A5 JP 2022542447 A5 JP2022542447 A5 JP 2022542447A5 JP 2022506467 A JP2022506467 A JP 2022506467A JP 2022506467 A JP2022506467 A JP 2022506467A JP 2022542447 A5 JP2022542447 A5 JP 2022542447A5
Authority
JP
Japan
Prior art keywords
amino acid
residue corresponding
acid residue
hla class
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506467A
Other languages
English (en)
Japanese (ja)
Other versions
JP7811540B2 (ja
JP2022542447A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/057173 external-priority patent/WO2021019473A1/en
Publication of JP2022542447A publication Critical patent/JP2022542447A/ja
Publication of JP2022542447A5 publication Critical patent/JP2022542447A5/ja
Application granted granted Critical
Publication of JP7811540B2 publication Critical patent/JP7811540B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506467A 2019-07-30 2020-07-29 Mhcクラスii分子及びその使用方法 Active JP7811540B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962880501P 2019-07-30 2019-07-30
US62/880,501 2019-07-30
US202063029114P 2020-05-22 2020-05-22
US63/029,114 2020-05-22
PCT/IB2020/057173 WO2021019473A1 (en) 2019-07-30 2020-07-29 Mhc class ii molecules and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022542447A JP2022542447A (ja) 2022-10-03
JP2022542447A5 true JP2022542447A5 (cg-RX-API-DMAC7.html) 2023-08-08
JP7811540B2 JP7811540B2 (ja) 2026-02-05

Family

ID=74228599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506467A Active JP7811540B2 (ja) 2019-07-30 2020-07-29 Mhcクラスii分子及びその使用方法

Country Status (12)

Country Link
US (1) US12590139B2 (cg-RX-API-DMAC7.html)
EP (1) EP4004034A4 (cg-RX-API-DMAC7.html)
JP (1) JP7811540B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220052943A (cg-RX-API-DMAC7.html)
CN (1) CN114450302B (cg-RX-API-DMAC7.html)
AU (1) AU2020322246B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001710A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146292A1 (cg-RX-API-DMAC7.html)
IL (1) IL290223A (cg-RX-API-DMAC7.html)
MX (1) MX2022001210A (cg-RX-API-DMAC7.html)
TW (1) TW202116797A (cg-RX-API-DMAC7.html)
WO (1) WO2021019473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
US20220291215A1 (en) * 2019-07-30 2022-09-15 University Health Network Methods of identifying t cell receptors
TWI881991B (zh) * 2019-07-30 2025-05-01 大學健康網絡 Ii類mhc分子及其使用方法
CN118662607B (zh) * 2023-03-15 2026-07-07 中国科学院上海药物研究所 抑制过激炎性反应的蛋白及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7025964B1 (en) 1996-11-13 2006-04-11 Meiji Dairies Corporation Peptide-based immunotherapeutic agent
WO2002059143A2 (en) * 2001-01-24 2002-08-01 President And Fellows Of Harvard College Therapeutic peptides for demyelinating conditions
GB0107628D0 (en) 2001-03-27 2001-05-16 Avidex Ltd Substances
EP1403283A4 (en) 2001-06-12 2006-05-10 Greenpeptide Co Ltd TUMOR ANTIGEN
WO2005045027A1 (ja) * 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Wt1由来のhla−dr結合性抗原ペプチド
CN101001868A (zh) 2004-06-17 2007-07-18 曼康公司 表位类似物
US20060228758A1 (en) 2004-09-13 2006-10-12 Xencor, Inc. Analysis of MHC-peptide binding interactions
US20060084116A1 (en) 2004-09-13 2006-04-20 Xencor, Inc. Analysis of MHC-peptide binding interactions
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2016135363A1 (es) 2015-02-23 2016-09-01 Servicio Andaluz De Salud Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c
JP2018528191A (ja) 2015-08-19 2018-09-27 ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
JP2019521080A (ja) 2016-04-27 2019-07-25 ユニバーシティ・ヘルス・ネットワーク ペプチド−hla複合体およびその産生方法
CA3084674A1 (en) 2017-12-23 2019-06-27 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
TWI881991B (zh) 2019-07-30 2025-05-01 大學健康網絡 Ii類mhc分子及其使用方法
US20220291215A1 (en) 2019-07-30 2022-09-15 University Health Network Methods of identifying t cell receptors
KR20220052944A (ko) 2019-07-30 2022-04-28 유니버시티 헬스 네트워크 Mhc 클래스 ii 분자 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP7270001B2 (ja) Mhcクラスii拘束性mage-a3を認識するt細胞受容体
JP2022542448A5 (cg-RX-API-DMAC7.html)
JP2022050400A (ja) 抗kras-g12d t細胞受容体
CN118994363A (zh) 抗突变的kras的t细胞受体
EP3095792A1 (en) T cell receptor with specificity for myeloperoxidase peptide and uses thereof
JP2016531583A5 (cg-RX-API-DMAC7.html)
JP5936129B2 (ja) REIC/Dkk−3タンパク質の部分領域ポリペプチド
JP2018534255A5 (cg-RX-API-DMAC7.html)
CN116515765A (zh) Cll1-car-t细胞及其制备方法与应用
JP7811540B2 (ja) Mhcクラスii分子及びその使用方法
JP2024509904A5 (cg-RX-API-DMAC7.html)
CN108277205A (zh) 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途
CN113179631A (zh) 通过临近使能反应疗法开发的共价蛋白质药物
CN111892661A (zh) 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用
CA3107859A1 (en) Mr1 restricted t cell receptors for cancer immunotherapy
Harrison et al. Distribution and expression of CD44 isoforms and Ezrin during prostate cancer-endothelium interaction
CN116635427A (zh) 嵌合抗原受体
AU2015346350A2 (en) Anti-thyroglobulin t cell receptors
IT202000006973A1 (it) Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro
US12594302B2 (en) Single domain antibodies and their use in cancer therapies
CN114891815A (zh) Dna片段、表达载体、嵌合抗原受体t细胞、应用
TWI881991B (zh) Ii類mhc分子及其使用方法
CN108290940A (zh) Tcr及其用途
WO2024263821A2 (en) Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
JP2024505111A (ja) 改善された抗がん活性を有するt細胞の選択方法